ORUM (475830) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ORUM (475830) has a cash flow conversion efficiency ratio of -0.128x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-15.34 Billion ≈ $-10.39 Million USD) by net assets (₩119.57 Billion ≈ $81.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 475830 stock market capitalisation for the company's overall valuation and market capitalisation.
ORUM - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how ORUM's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ORUM Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ORUM ranked by their cash flow conversion efficiency. Explore ORUM cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kodiak AI, Inc. Common Stock
NASDAQ:KDK
|
-0.996x |
|
Sanofi India Limited
NSE:SANOFI
|
0.585x |
|
Vina Concha To
SN:CONCHATORO
|
-0.032x |
|
HomeTrust Bancshares, Inc.
NYSE:HTB
|
0.187x |
|
DoubleU Games Co Ltd
KO:192080
|
0.031x |
|
ADLINK Technology Inc
TW:6166
|
0.098x |
|
Verusa Holding AS
IS:VERUS
|
-0.014x |
|
Kyobo Securiti
KO:030610
|
0.054x |
Annual Cash Flow Conversion Efficiency for ORUM (2022–2025)
The table below shows the annual cash flow conversion efficiency of ORUM from 2022 to 2025. View 475830 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩130.89 Billion ≈ $88.70 Million |
₩-35.99 Billion ≈ $-24.39 Million |
-0.275x | -196.77% |
| 2024-12-31 | ₩121.76 Billion ≈ $82.52 Million |
₩-11.28 Billion ≈ $-7.65 Million |
-0.093x | +94.48% |
| 2023-12-31 | ₩-56.18 Billion ≈ $-38.07 Million |
₩94.24 Billion ≈ $63.87 Million |
-1.678x | -620.35% |
| 2022-12-31 | ₩-127.46 Billion ≈ $-86.38 Million |
₩-41.09 Billion ≈ $-27.85 Million |
0.322x | -- |
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid … Read more